Janux Therapeutics (JANX) Institutional Ownership

75.39% of Janux Therapeutics' stock is owned by institutional investors. Learn more on JANX's institutional investor holdings.

Of the 197 institutional investors that purchased Janux Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BlackRock Inc. ($6.13M), Janus Henderson Group PLC ($2.41M), Wellington Management Group LLP ($2.16M), RA Capital Management L.P. ($2.02M), State Street Corp ($1.96M), Bank of America Corp DE ($1.82M), and Prosight Management LP ($1.66M).

Institutional investors have bought a total of 23,116,256 shares in the last 24 months. This purchase volume represents approximately $357.27M in transactions.

Of the 53 institutional investors that sold Janux Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Adage Capital Partners GP L.L.C. ($2.38M), Janus Henderson Group PLC ($1.15M), Orbimed Advisors LLC ($970.83K), Readystate Asset Management LP ($850.95K), Franklin Resources Inc. ($683.89K), Price T Rowe Associates Inc. MD ($521.09K), and Logos Global Management LP ($435K).

Institutional investors have sold a total of 9,817,051 shares in the last 24 months. This volume of shares sold represents approximately $153.90M in transactions.